This pathophysiology diagram illustrates the glycolysis pathway as a therapeutic target for anti-inflammatory strategies. The metabolic flowchart depicts the sequence from glucose entry via the Glut1 transporter through various intermediates including glucose-6-phosphate, fructose-1,6-bisphosphate, and glyceraldehyde-3-phosphate, culminating in pyruvate entry into the Krebs cycle within the mitochondria. Key regulatory interventions are highlighted: 2-DG (2-deoxyglucose) inhibiting hexokinase to treat inflammatory diseases like SLE, RA, and Guillain-Barré; Heptelidic Acid inhibiting GAPDH for neuroprotective and anti-inflammatory effects; and TEPP-46 promoting the tetramerization of Pyruvate Kinase M2 to inhibit pro-inflammatory markers in sepsis, EAE, and AKI. The diagram identifies specific immune cell types affected by these interventions, such as Th1, Th17, macrophages, and NK cells. The educational focus is on how modulating metabolic enzymes can alter immune cell phenotype and manage systemic inflammatory conditions.

This pathophysiology diagram illustrates the metabolic mechanisms of the glycogen pathway in Lactobacillus acidophilus and its role in probiotic functionality. The diagram shows carbohydrate substrates being imported into the intracellular space through membrane-bound carbohydrate transporters. Once inside, these substrates follow two primary pathways: immediate metabolic processing via glycolysis or diversion to the glycogen biosynthetic pathway to form an intracellular 'carbon pool'. A bidirectional red arrow indicates a regulatory feedback loop between glycolysis and glycogen storage to modulate carbon downflow and energy flux. The glycogen pool is shown to serve three critical functions: regulation of metabolic flux, providing energy for maintenance and stress response, and supporting other crucial cellular processes. These physiological roles collectively contribute to the bacterium's clinical and probiotic attributes, including enhanced bile and stress tolerance, prolonged survival and retention in the GI tract, and improved in vivo competitive fitness within diverse environments such as the dairy matrix and processing facilities.

This pathophysiology diagram illustrates the metabolic reprogramming of a cell, specifically focusing on the Warburg effect and altered glucose metabolism common in cancer biology. The diagram depicts the plasma membrane featuring multiple glucose transporters, including SGLT1-2 (sodium-coupled), GLUT1, GLUT4, and GLUT8, which facilitate increased glucose uptake. The primary glycolytic pathway is shown progressing from Glucose to Glu-6-P (via HK), through Fru-6-P, Fru-1,6-P, GA3P, and PEP, ultimately leading to Pyruvate and Lactate (via LDHA). Parallel to glycolysis, the Pentose Phosphate Pathway (PPP) is detailed, converting G6P to Ribose-5-P while generating NADPH for redox homeostasis (GSH/GSSG balance) to mitigate ROS. Key regulatory mediators are highlighted: HIF-1 and MYC stimulate glucose transporters and glycolytic enzymes; TGFB and FGF influence PKM2 and LDHA activity; p53 regulates the process through TIGAR to inhibit Fru-2,6-P. The visual summarizes how oncogenic signaling (including KRAS) drives aerobic glycolysis and pentose production to support rapid cell proliferation and antioxidant defense.

This medical pathophysiology diagram illustrates the heme biosynthesis pathway and its associated acute hepatic porphyrias. The flow is depicted across two cellular compartments: the mitochondria and the cytoplasm. The pathway begins in the mitochondria where Succinyl-CoA and Glycine are converted by ALAS (delta-aminolevulinic acid synthase) into delta-aminolevulinic acid (ALA). The process then moves to the cytoplasm, proceeding through intermediates: porphobilinogen (PBG), hydroxymethylbilane, uroporphyrinogen III, and coproporphyrinogen III, facilitated by enzymes ALAD, HMBS, UROS, and UROD respectively. The final stages return to the mitochondria, where coproporphyrinogen III is converted to protoporphyrinogen and then protoporphyrin IX via CPOX and PPOX. In the final step, ferrochelatase (FECH) incorporates iron (Fe) into protoporphyrin IX to form heme. The diagram explicitly links specific enzyme deficiencies to clinical conditions: ALAD deficiency porphyria (ADP), acute intermittent porphyria (AIP), hereditary coproporphyria (HCP), and variegate porphyria (VP). The visual uses chemical structures, enzyme labels, and mitochondrial representation to detail the metabolic sequence.

This composite educational infographic illustrates the pathophysiology of Porphyria Cutanea Tarda (PCT) through three integrated sections. Section A depicts the normal heme biosynthesis pathway in the liver, showing the enzymatic conversion starting from Glycine and Succinyl CoA, through intermediates like ALA, PBG, HMB, and Uroporphyrinogen III, catalyzed by enzymes including ALAS, ALAD, and UROD, culminating in HEME production. Section B focuses on the molecular pathogenesis of PCT, highlighting the inhibition of the enzyme Uroporphyrinogen Decarboxylase (UROD). This block leads to the accumulation of porphyrins, which is visually linked to a large chemical structure diagram. Section C demonstrates the clinical manifestation of this metabolic defect. It shows a human arm with a magnified view of cutaneous bullae (blisters) and a sun icon, illustrating how light-activated porphyrins cause mast cell degranulation and oxidative damage to skin layers. The diagram serves as an educational tool for understanding the link between hepatic enzymatic deficiencies and dermatological photosensitivity.

A pathophysiology diagram illustrating cholesterol metabolism, lipoprotein circulation, and Reverse Cholesterol Transport (RCT). The process is divided into exogenous, endogenous, and HDL pathways. In the exogenous pathway, the gut produces chylomicrons (CM), which are hydrolyzed by Lipoprotein Lipase (LPL) into CM remnants for hepatic uptake via SR-BI and Hepatic Lipase (HL) mediation. The endogenous pathway shows the liver secreting VLDL, which matures into LDL; LDL returns to the liver via the LDL receptor (LDLR), a process regulated by PCSK9 and CETP. The RCT/HDL pathway features Nascent HDL (APOA-associated) acquiring cholesterol from macrophages through ABCA1 and ABCG1 transporters. Maturation from FC-rich HDL3 to CE-rich HDL2 and HDL1 is catalyzed by LCAT. Specialized hepatic uptake occurs via SR-BI. On the right, a macrophage is shown accumulating oxidized LDL (oxLDL) via CD36 and SR-A receptors, leading to foam cell formation, regulated by PPARγ and LXR nuclear receptors. Numbered annotations (1-9) indicate potential therapeutic targets for phytochemicals to accelerate RCT and reduce atherosclerosis.

A pathophysiology diagram illustrating the pathways of cholesterol metabolism across four compartments: Enterocyte, Blood Vessel, Liver, and Intestinal Lumen/Bile Duct. Dietary cholesterol enters the enterocyte via the NPC1L1 transporter and is packaged into chylomicrons (CM). CMs enter the blood vessel and undergo conversion into very low-density lipoprotein (VLDL) and then low-density lipoprotein (LDL). LDL is taken up by the liver via the LDL receptor (LDLR). Within the liver, cholesterol can be converted into cholesterol esters to form nascent VLDL for secretion back into the blood vessel, or it can be excreted into the intestinal lumen/bile duct for potential reabsorption via NPC1L1. The diagram also shows reverse cholesterol transport: free liver cholesterol is transferred to the blood via ABCA1, where it combines with apoA-I to form high-density lipoprotein (HDL). HDL then returns cholesterol to the liver through the SR-BI receptor. This diagram highlights key lipoproteins (CM, VLDL, LDL, HDL) and regulatory proteins (NPC1L1, LDLR, ABCA1, SR-BI) involved in systemic lipid homeostasis.

This systems biology infographic outlines a multi-omics approach to biomarker discovery and validation. The diagram is organized by biological flow, starting with molecular central dogma processes: replication (DNA), transcription (mRNA), and translation (protein). Four primary 'omics' fields are highlighted in red boxes: Genomics, Proteomics, Metabolomics, and Lipidomics. Each field is mapped to specific high-throughput analytical technologies in blue boxes. Genomics uses Illumina HiSeq 3000 RNA-Seq to analyze Transcriptomics and Micro-RNAs. Proteomics utilizes 2D nanospray LC-HRMS/MS (Thermo Q-Exactive HF) for protein quantitation and post-translational modification analysis. Lipidomics and Metabolomics employ micro-ionspray LC-HRMS/MS for lipid and metabolite quantitation. The flowchart illustrates how these diverse data streams converge into a centralized 'Bioinformatics Emerald Logic' node. This educational visual demonstrates the integration of genomic, proteomic, and metabolic data using sophisticated signal processing for comprehensive biomarker profiling in clinical research and drug development.

This pathophysiology diagram illustrates the role of folic acid in cellular methylation and its impact on human embryonic development. The flow begins with folic acid acting as a precursor to provide methyl donors (such as S-adenosylmethionine). A central dashed box highlights the epigenetic regulation of the central dogma: DNA, RNA, and proteins. Within this box, green arrows represent the transcription of DNA to RNA and the translation of RNA to protein. To the right, internal methylation reactions—catalyzed by methyltransferases—are shown adding methyl groups (indicated by 'Me' icons) to these macromolecules. The diagram outlines that these methylation processes directly impact critical biological functions, including DNA and RNA synthesis, embryo development, neural tube formation, and the cell cycle. The final pathway leads to an illustration of an infant with an open neural tube defect (anencephaly/encephalocele), visually demonstrating how disruptions in the folic acid-driven methylation cycle can lead to congenital malformations known as neural tube defects (NTDs).

Bright-field light microscopy of a Gram-stained bacterial smear reveals numerous small, slender, curved Gram-negative rods with a characteristic gull-wing appearance consistent with Campylobacter species. The image captures bacteria oriented individually and in small clusters against a pale pink counterstain, illustrating Bacillary morphology typical of enteric pathogens. Gram staining shows purple/blue rods (crystal violet retained by cell wall) with a light pink background from the counterstain (safranin), enabling discrimination from Gram-positive organisms. The organisms appear slender and curved, with a single polar flagellum suggested by motility or alignment in the smear. Specimen type is a bacterial smear obtained from a gastrointestinal sample (feces or culture isolate), prepared for diagnostic microbiology. The imaging modality is bright-field microscopy at high magnification (approximately 1000x with oil immersion), following Gram staining to highlight bacterial cell wall structure. Clinically, detection of Campylobacter species supports infectious gastroenteritis; in the IPSID (immunoproliferative small intestinal disease) context, Campylobacter involvement has been proposed as a pathogenic trigger mirroring Helicobacter pylori's role in gastric MALT lymphoma. Differential diagnoses include Helicobacter, Vibrio, and other curved Gram-negative bacteria. This image serves educational and diagnostic utility for microbiology, clinical pathology, gastroenterology, and infectious disease research.

This diagnostic image shows a light microscopy view of a bacterial culture following Gram staining. The specimen displays numerous small, rod-shaped (bacilli) bacteria distributed across the field. The microorganisms exhibit a consistent pink-to-red hue, identifying them as Gram-negative. This staining characteristic indicates a cell wall structure with a thin peptidoglycan layer and an outer membrane that does not retain the crystal violet stain. The arrangement of the bacilli is predominantly individual or scattered, with occasional small clusters and pairs. Specifically identified as D. fastidiosa strain JC13T, this image serves as a primary microbiological reference for the morphological and staining properties of this novel genus within the family Erysipelotrichaceae. The visual demonstrates key diagnostic features including cell morphology, arrangement, and Gram reaction, which are essential for clinical microbiology classification and initial pathogen identification.

This diagnostic micrograph displays a Gram-stained smear of Pedobacter schmidteae strain EGT, a Gram-negative bacterium. The image shows a high density of pink/red stained bacterial cells, a color characteristic of Gram-negative organisms that do not retain crystal violet but take up the safranin counterstain. The morphology of the bacteria is consistently rod-shaped (bacilli). The cells are predominantly arranged individually or in loose, disorganized clusters, and are distributed across a relatively clear background with uniform staining intensity. This visual is representative of microbiology laboratory techniques used for the preliminary classification and morphological identification of bacterial isolates based on cell wall composition and shape.

This composite figure illustrates the multi-organ manifestations of Mycobacterium tuberculosis in a primate model, showcasing diagnostic imaging, gross pathology, and histopathology. Panel (a) is a chest radiograph showing diffuse pulmonary infiltrates. Panels (b), (c), and (d) present gross pathology of the lungs, spleen, and liver respectively, highlighting numerous pale, nodular granulomatous lesions across the organ surfaces. Panels (e), (f), and (g) are Hematoxylin and Eosin (H&E) stained sections of lung tissue at varying magnifications (12.5x to 200x). They demonstrate classic granulomatous inflammation with central amorphous caseous necrosis and surrounding inflammatory cell infiltration. Panels (h) and (i) show high-magnification (1000x) Ziehl-Neelsen stains of the lung tissue, specifically identifying several acid-fast bacilli (AFB) visible as small, bright red-pink rods (indicated by arrows) against a blue methylene counterstain. This progression from clinical radiology to microscopic confirmation of AFB and caseating granulomas illustrates the typical diagnostic pathway for systemic tuberculosis.

This diagnostic image is a high-power light microscopy field showing a histopathological sample stained with Ziehl-Neelsen or a similar acid-fast stain. The background consists of blue-stained cellular debris, fibrous tissue, and inflammatory infiltrates from a pericardial biopsy. Centrally highlighted within a red circular annotation are several bright red or pink, rod-shaped microorganisms. These characteristics are pathognomonic for acid-fast bacilli (AFB), specifically Mycobacterium tuberculosis. The visual demonstrates the diagnostic findings of tuberculous pericarditis, where the pathogen is directly visualized within the pericardial tissue despite a non-granulomatous histological appearance. This slide serves as an educational example of infectious pathology and the clinical utility of specialized staining in identifying extracellular pathogens in extrapulmonary tuberculosis.

A multi-modal comparison of invasive fungal tracheobronchitis (IFT) caused by Aspergillus, Candida, and Mucorales. The composite consists of nine panels (a-i) organized by diagnostic modality. Panels a-c: Chest radiographs showing diffuse, bilateral pulmonary infiltrates and consolidations common across different fungal etiologies. Panels d-f: Bronchoscopic views demonstrating various endobronchial manifestations: (d) extensive pseudomembranous and ulcerative lesions with irregular surfaces (Aspergillus), (e) smooth whitish pseudomembranes (Candida), and (f) focal whitish plaques with associated airway inflammation (Mucorales). Panels g-i: Histopathological microscopy (400x magnification, 20 µm scale bars) highlighting diagnostic morphology: (g) septate hyphae with characteristic 45-degree acute-angle branching (Aspergillus), (h) yeast cells and elongated pseudohyphae (Candida), and (i) a mixed infection showing broad, thin-walled, non-septate hyphae (Mucormycete) alongside septate Aspergillus hyphae. This comparison illustrates that while radiographic and bronchoscopic findings may overlap, histopathology is critical for differentiating the specific fungal species in immunocompromised or critically ill patients.

A comparative medical display illustrating fungal keratitis findings across three different pathogenic fungi: Candida albicans, Fusarium solani, and Aspergillus fumigatus. The visual content is organized in a matrix format showcasing three diagnostic modalities: slit-lamp biomicroscopy, 10% KOH smear, and confocal microscopy. Slit-lamp images demonstrate distinct corneal macroscopic variations: Candida shows a dense, white, opaque infiltrate; Fusarium presents with a reddish-pink corneal hue and a focal light reflex; and Aspergillus exhibits dark, pigmented necrotic areas with surface irregularity. The 10% KOH smears reveal microscopic fungal morphology, highlighting branching hyphae in Fusarium and spherical structures with radiating filaments in Aspergillus against an orange-stained background. Confocal microscopy panels provide high-resolution cellular views, showing bright punctate spots for Candida and dense, interconnected filamentous networks for Fusarium and Aspergillus. This resource serves as an educational guide for differentiating fungal etiologies in infectious keratitis through clinical and microbiological correlation.

Educational diagram illustrating the genome organization of Foamy Virus (FV) and comparing replication strategies among reverse-transcribing viruses. Panel (A) depicts the FV genome structure, showing the 5' and 3' long terminal repeats (LTRs) flanking the structural genes (gag, pol, env) and the accessory genes (bel1 and bel2). A unique internal promoter (IP) is located within the env gene, driving the transcription of the Bet protein, a spliced product composed of bel1 and bel2 sequences. Panel (B) presents a comparative pathophysiology flowchart for three virus groups: Orthoretrovirinae (HIV), Spumaretrovirinae (FV), and Hepadnaviridae (HBV). The comparison highlights three key divergent mechanical features: 1. Reverse Transcription (RT) Timing: HIV performs early RT, whereas FV and HBV perform late RT. 2. Genomic Integration: Retroviridae (HIV and FV) undergo chromosomal integration, while HBV does not. 3. Budding Mechanism: HIV budding is envelope (Env)-independent, whereas FV and HBV require specific Env-glycoprotein interactions for viral release. The diagram uses standard notation where blue lines represent RNA and brown lines represent DNA molecules.

This medical illustration depicts the genome structure and replication cycle of a flavivirus, such as Dengue or Zika virus. Panel A shows the positive-sense single-stranded RNA genome, featuring a 5' cap, 5' UTR, and 3' UTR flanking a single large open reading frame. This ORF encodes three structural proteins (Capsid [C], pre-Membrane [prM], and Envelope [E]) followed by seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). Panel B illustrates the viral life cycle within a host cell. Key stages shown include: 1) Binding to surface receptors; 2) Clathrin-mediated endocytosis; 3) pH-dependent uncoating and RNA release; 4) Translation and RNA replication at the endoplasmic reticulum (ER); 5) Viral assembly within the ER; 6) Transport and maturation through the trans-Golgi network; and 7) Release of mature virions via exocytosis. The diagram serves as an educational tool for understanding virology, infectious diseases, and potential targets for antiviral therapy.

A pathophysiology diagram illustrating how various bacterial and viral pathogens target host Ubc9 stability to facilitate infection. Centrally, a purple diamond represents Ubc9, the essential E2 conjugating enzyme of the SUMOylation pathway. Surrounding Ubc9 are five bacterial genera (Clostridium, Streptococcus, Listeria, Shigella, and Salmonella) and one virus (Adenovirus), each connected by arrows indicating the secretion of specific toxins or proteins: Perfringolysin, Pneumolysin, Listeriolysin, Shigella toxin, and Gam1, respectively. A vertical downward arrow shows the transition from intact Ubc9 to a fragmented 'Degraded Ubc9' representation. The diagram concludes with a final stage labeled 'Comprehensive perturbation in host SUMOylation processes assisting infection,' demonstrating the clinical significance of Ubc9 degradation. This visual summary emphasizes the mechanism by which pathogens destabilize the host's cellular defense and signaling by compromising the unique E2 enzyme required for protein SUMOylation, thereby suppressing innate immune responses and promoting pathogenesis.

A pathophysiology diagram illustrating the mechanism of bacteriophage infection of Staphylococcus bacteria. The visual depicts two greenish-yellow, spherical cocci with irregular, textured surfaces. The rightmost bacterium is shown in a cross-sectional view, revealing its internal cavity and genetic material, represented as a circular double-helix DNA plasmid in blue and red. At the bacterial cell wall, a bacteriophage (virus) is shown as a complex, geometric structure with a polygonal head and leg-like appendages docked onto the surface. The diagram highlights the injection process, with red particles (viral genetic material) flowing from the phage into the bacterial cytoplasm and accumulating near the point of attachment. This image serves as an educational model for microbiology and infectious disease, specifically demonstrating viral transduction and the potential therapeutic use of phages against biofilms formed on medical devices like needleless intravenous connectors.

This pathophysiology diagram illustrates the mechanisms underlying undetectable Hepatitis B surface antigen (HBsAg) in patients who are HBeAg-positive and anti-HBs-positive. The diagram is divided into two primary pathways: the formation of Circulating Immune Complexes (CICs) and the emergence of HBsAg mutants. In the CIC pathway, HBsAg particles are shown in circulation bound by Y-shaped anti-HBs antibodies; this 'masking' of epitopes renders the antigen undetectable by standard assays. A lower panel demonstrates that chemical dissociation or specialized assays (e.g., Lumipulse HBsAg-HQ) can unmask these antigens, making them detectable. The second pathway shows 'Immune escape-associated HBsAg mutants' arising from antibody selective pressure. These are depicted as spheres, filaments (together termed subviral particles or SVPs), and complete virions with altered surface epitopes (marked by purple stars). Both CIC formation and mutant emergence contribute to the diagnostic challenge of occult Hepatitis B infection (OBI). This diagram is intended for intermediate to advanced medical education regarding HBV serology, diagnostic pitfalls, and immune escape mechanisms.

Summary : This figure presents two line plots showing the typical serologic courses of acute and chronic hepatitis B virus (HBV) infection, comparing the progression and recovery of serologic markers over time. line plot: # Panel A: Typical serologic course of acute HBV infection to recovery ## Title & Axes : • Title: "A. Typical serologic course of acute HBV infection to recovery" • X-axis: "Weeks after exposure" (tick labels: 0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 52, 100) • Y-axis: "Relative concentration" (no explicit tick labels) • Additional timeline annotations: "HBV DNA", "Symptoms", "HBeAG", "Anti-HBe" (horizontal arrows above plot) ## Data Points : • HBsAg (solid line): Rises sharply after exposure, peaks around 8–12 weeks, then declines and disappears by ~24–28 weeks. • Total anti-HBc (dashed line): Rises after exposure, peaks around 16–20 weeks, remains elevated beyond 100 weeks. • IgM anti-HBc (dotted line): Rises after exposure, peaks around 12–16 weeks, declines and disappears by ~28–32 weeks. • Anti-HBs (long dashed line): Appears after ~24–28 weeks, rises and remains elevated beyond 100 weeks. ## Design Encodings : • HBsAg: solid purple line • Total anti-HBc: dashed purple line • IgM anti-HBc: dotted purple line • Anti-HBs: long dashed purple line • All lines plotted against the same axes; no log scale or error bars. ## Distribution & Trends : • HBsAg and IgM anti-HBc both show transient peaks and then decline. • Total anti-HBc and anti-HBs persist long-term after recovery. # Panel B: Typical serologic course of progression to chronic HBV infection ## Title & Axes : • Title: "B. Typical serologic course of progression to chronic HBV infection" • X-axis: "Weeks after exposure" (tick labels: 0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 52), then "Years" (break in axis) • Y-axis: "Relative concentration" (no explicit tick labels) • Additional timeline annotations: "HBV DNA", "Acute (6 months)", "Chronic (years)", "HBeAG", "Anti-HBe" (horizontal arrows above plot) ## Data Points : • HBsAg (solid line): Rises after exposure, remains persistently elevated for years. • Total anti-HBc (dashed line): Rises after exposure, remains persistently elevated for years. • IgM anti-HBc (dotted line): Rises after exposure, peaks around 12–16 weeks, declines and disappears by ~28–32 weeks. ## Design Encodings : • HBsAg: solid purple line • Total anti-HBc: dashed purple line • IgM anti-HBc: dotted purple line • All lines plotted against the same axes; no log scale or error bars. ## Distribution & Trends : • HBsAg and total anti-HBc remain persistently elevated in chronic infection. • IgM anti-HBc is transient and disappears after the acute phase. # Analysis : • In acute HBV infection (Panel A), HBsAg and IgM anti-HBc are transient, while total anti-HBc and anti-HBs persist after recovery, indicating resolution and immunity. • In chronic HBV infection (Panel B), HBsAg and total anti-HBc remain persistently elevated for years, while IgM anti-HBc is only present during the acute phase, indicating ongoing infection without resolution. • The presence and duration of serologic markers distinguish acute recovery from progression to chronic infection.

A pathophysiology diagram illustrating the complex life cycle of the Plasmodium parasite, responsible for malaria, between a female Anopheles mosquito and a human host. The cycle is divided into two primary environments. Within the human host, the parasite undergoes liver stages, where sporozoites infect hepatocytes and multiply into merozoites. This is followed by the blood stages, an asexual intraerythrocytic cycle where merozoites infect red blood cells (RBCs) and progress through ring, trophozoite, and schizont stages before rupturing to infect new RBCs. Sexual differentiation occurs when some merozoites develop into male and female gametocytes. The mosquito stages begin when a mosquito ingests these gametocytes during a blood meal. Within the mosquito's midgut and salivary glands, the parasite undergoes sexual reproduction and development, progressing from gametes to zygote, ookinete, and oocyst. The mature oocyst releases sporozoites that migrate to the mosquito's salivary glands for transmission back to a human host, completing the cycle. This educational diagram is essential for understanding parasitology, infectious disease transmission, and the biological targets for malaria treatment and prevention.

A medical educational diagram illustrating the Intra-erythrocytic Development Cycle (IDC) of the malaria parasite (Plasmodium spp.). The flowchart depicts two divergent pathways within a host red blood cell (RBC). The primary loop shows the asexual replication cycle, where parasites (teal circles) undergo maturation from a single parasite body into schizonts with multiple internal bodies, eventually bursting to release merozoites for further RBC infection. A secondary pathway illustrates sexual commitment, marked by the expression of the transcription factor AP2-G (represented by purple circles). Following this commitment, the parasites differentiate into sexual stages called gametocytes (yellow circles). The final stage of this differentiation demonstrates the formation of distinct male and female gametocytes, identified by gender symbols. The diagram highlights the biological decision-making process between continued asexual multiplication for within-host survival and the production of gametocytes for transmission to the mosquito vector, a key concept in malaria pathophysiology and lifecycle research.

This infographic and diagnostic image set illustrates the antibacterial mechanism of a CIP-Ag/TiO2/Fe2O3/CS nanoformulation against multi-drug resistant (MDR) E. coli. The left side features a pathophysiology diagram depicting a bacterial cell undergoing the following stages: 1) Electrostatic attraction between the positively charged nanoformulation and the negatively charged cell wall leading to attachment and penetration; 2) Ionization and release of Ag+, Fe+, and Ti+ ions intracellularly, triggering Reactive Oxygen Species (ROS) production. Annotated mechanisms include porin mimicry, motility inhibition, and lethal damage to intracellular components. The right side contains an electron microscopy (FESEM) image labeled 'Lysis of MDR E. coli,' showing lysed, deflated, and irregularly shaped bacterial cells with disrupted membrane integrity. A corresponding text box summarizes oxidative stress outcomes: cell wall damage, inhibition of DNA and protein synthesis, blocking of the electron transport chain, and interruption of signal transduction. This educational content demonstrates targeted drug delivery and bactericidal activity relevant to treating antibiotic-resistant infections like bovine or human mastitis.

A medical pathophysiology diagram illustrating the mechanism of action of Catharanthus roseus root ethanolic extract (EECRR) in sensitizing multiple antibiotic-resistant Staphylococcus aureus (MAR-SA) to ampicillin. The flowchart transitions from left to right, starting with a bacterial colony of MAR-SA and a test tube representing the extract. It branches into two treatment pathways: 'Ampicillin + 1/2 MIC EECRR', which results in decreased cell viability, and 'Ampicillin + MIC EECRR', which leads to cell death (indicated by a red cross). The right side of the diagram provides a molecular level illustration of a MAR-SA cell. It demonstrates that the EECRR treatment inhibits penicillin-binding protein 2a (PBP2a), which normally blocks ampicillin. By suppressing PBP2a expression and causing plasmid DNA damage, the extract allows ampicillin to bind to PBP2, disrupting the bacterial cell wall integrity. Key labels include PBP2a, PBP2, ampicillin, plasmid, and DNA damage. This visual summarizes an antimicrobial research study on overcoming antibiotic resistance using botanical extracts.

<table><thead><tr><th>Opportunistic Infection</th><th>Preferred Therapy</th><th>Alternative Therapy</th><th>Other Comments</th></tr></thead><tbody><tr><td>Bacterial Enteric Infections</td><td>Empiric Therapy Pending Definitive Diagnosis</td><td>For People With HIV and CD4 Count >500 Cells/mm³, 1–2 Days of Loose Stool Without Fever or Blood in Stool<br><br>• Oral hydration, no further workup, and no antibiotics<br><br>For People With HIV and CD4 Count 200–500 Cells/mm³ With Diarrhea Severe Enough to Compromise Quality of Life or the Ability to Work<br><br>• Azithromycin 500 mg PO daily for 5 days (BIII), or<br><br>• Ciprofloxacin 500–750 mg PO every 12 hours for 5 days (BIII)<br><br>For People With HIV and Severe Disease (e.g., CD4 Count <200 Cells/mm³ or Concomitant AIDS-Defining Illness and With Clinically Severe Diarrhea [≥6 Liquid Stools Per Day or Bloody Stool and/or Accompanying Fever or Chills])<br><br>• Hospitalization for diagnostic evaluation and IV antibiotics<br><br>• Ceftriaxone IV 1–2 g every 24 hours (BIII)<br><br>Note: If Campylobacter or Shigella bacteremia is suspected, a carbapenem is preferred (BIII).<br><br>Therapy and duration should be adjusted based on microbiology and antibiotic sensitivity results.<br><br>If no pathogen is identified and the patient recovers quickly, 5 days of therapy is recommended.</td><td></td><td>Diagnostic fecal specimens should be obtained before initiation of empiric antimicrobial therapy.<br><br>If a pathogen is identified, antibiotic susceptibilities should be performed to confirm and inform antibiotic choices, given increased reports of antibiotic resistance.<br><br>Oral or IV rehydration (if indicated) should be given to patients with diarrhea (AIII).<br><br>Antimotility agents should be avoided if there is concern about inflammatory diarrhea, including CDI (BIII).<br><br>Risk of bacteremia increases with decreasing CD4 count.<br><br>If no clinical response is observed after 3–4 days, consider a follow-up stool culture with antibiotic susceptibility testing or alternative diagnostic tests (e.g., toxin assays, molecular testing) to evaluate alternative diagnoses, antibiotic resistance, or drug–drug interaction (BIII).<br><br>MSM may be at increased risk for antibiotic resistant enteric infections.</td></tr></tbody></table>

**Imaging Modality:** Contrast-enhanced axial Computed Tomography (CT) of the chest, displayed in lung window settings. **Anatomical Region:** Upper thoracic cavity at the level of the aortic arch and tracheal bifurcation. **Observed Pathology:** The image demonstrates bilateral, symmetric, and patchy-to-confluent air space opacities. The distribution is predominantly central and perihilar within the upper lung lobes. These findings are characterized by ground-glass attenuation and consolidation with ill-defined borders. **Characteristic Visual Features:** - **Air Bronchograms:** Visible within the areas of confluent consolidation. - **Distribution:** Central/perihilar "bat-wing" pattern with relative sparing of the extreme peripheral/subpleural lung parenchyma. - **Associated Features:** There is an absence of significant pleural effusions or overt mediastinal lymphadenopathy at this level. **Clinical Context:** In the setting of severe immunocompromise (HIV/AIDS with low CD4 count), these radiologic findings are highly suggestive of opportunistic infection, most notably *Pneumocystis jirovecii* pneumonia (PCP). **Differentiating Features:** The central upper lobe predominance and lack of pleural fluid help distinguish this pattern from typical bacterial pneumonia or cardiogenic pulmonary edema.